Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Bioanalysis|July 3, 2024
Solving selectivity issues in LBAs: case study using Gyrolab to quantify CB307, a bispecific Humabody in human serumThomas Wilford, Phillip D Bartlett, Anna Schlag, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 9, 2024
CB307: A Dual Targeting Costimulatory Humabody VH Therapeutic for Treating PSMA-Positive TumorsSophie Archer, Phillip M Brailey, Minjung Song, et al.
British Journal of Cancer|December 31, 2021
The multi-specific V<sub>H</sub>-based Humabody CB213 co-targets PD1 and LAG3 on T cells to promote anti-tumour activityCarolyn J Edwards, Angelica Sette, Carl Cox, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 17, 2025
A phase I dose escalation and cohort expansion study of CB307, a trispecific Humabody® against PSMA, CD137, and albumin in patients with PSMA-positive solid tumorsJohann S de Bono, Anja Williams, Ignacio Melero, et al.
Pageof 1